Meds A-Z

Imidacloprid

Detailed information about Imidacloprid

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of...

What it does:

When it's needed:

Call your vet sooner if you notice:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats. Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.

Commonly reported reactions:

(2 reports)
(1 reports)
(1 reports)

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Talk to a Vet / Find a Vet Near You

Image coming soon

Imidacloprid

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Elanco US Inc.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Elanco US Inc.

Form: Chewable Tablets, Liquid (Solution), Solution, Topical Solution

Identifiers:

ANADA: 200615 ANADA: 200638 ANADA: 200700 ANADA: 200701 ANADA: 200714 ANADA: 200716 ANADA: 200718 ANADA: 200721 ANADA: 200811 ANADA: 200818 NADA: 141208 NADA: 141251 NADA: 141254 NADA: 141435 NDC Package: 17030-023-01 NDC Package: 17030-023-03 NDC Package: 17030-025-01 NDC Package: 17030-025-06 NDC Package: 17030-043-01 NDC Package: 17030-043-06

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200700 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200714 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats. Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats. Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Most Reported Reactions

Cases	Species	Serious cases
2	Cat, Dog	0
1	Cat	1
1	Cat	1
1	Dog	1
1	Cat	0
1	Cat	0
1	Dog	0
1	Cat	0

Species coverage: Cat (21) Dog (11)

View detailed reaction table

Species	Seriousness	Frequency	Reports
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Serious	-	1
Cat	Non-serious	-	1
Cat	Serious	-	1
Cat	Serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Dog	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Non-serious	-	1
Cat	Unknown	-	-
Dog	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-
Cat	Unknown	-	-

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-054396

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 32 • Secondary summaries: 0

Official label facts

ANADA 200-700 FOI Summar.pdf · FOI
PARASEDGE® Multi for Dogs · SPL
FOI Summary oA 200-714 Approved November 24, 2021.pdf · FOI
Barrier® for cats · SPL
FOI Summary oA 200-818 Approved August 5, 2025.pdf · FOI
MoxiCloprid™ for Dogs · SPL
FOI Summary oA 200-718 Approved February 7, 2022.pdf · FOI
Barrier® for dogs · SPL
FOI Summary oA 200-811 Approved March 24, 2025.pdf · FOI
MoxiCloprid™ for Cats · SPL
FOI Summary sA 200-701 Approved February 9, 2023.pdf · FOI
FOI Summary oA 200-701 Approved June 10, 2021.pdf · FOI
PARASEDGE™ Multi for Cats · SPL
FOI Summary sA 200-721 Approved January 12, 2023.pdf · FOI
FOI Summary oA 200-721 Approved March 28, 2022.pdf · FOI
Midamox® for Cats · SPL
FOI Summary oA 200-716 Approved January 28, 2022.pdf · FOI
Midamox® for Dogs · SPL
UCM381705.pdf · FOI
UCM051438.pdf · FOI
Advantage Multi™ for Dogs · SPL
UCM381709.pdf · FOI
UCM051423.pdf · FOI
advantage multi™ for cats · SPL
UCM433795.pdf · FOI
advantus™ · SPL
FOI Summary oA 200-638 Approved May 27, 2020.pdf · FOI
IMOXI™ Topical Solution for Cats · SPL
FOI Summary oA 200-615 Approved December 19, 2019.pdf · FOI
IMOXI™ Topical Solution for Dogs · SPL
ucm117758.pdf · FOI
Advantage® DUO · SPL

Secondary summaries

No source yet.

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11585 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10973/PARASEDGE%C2%AE%20Multi%20for%20Dogs · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11607 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11695/Barrier%C2%AE%20for%20cats · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17355 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17608/MoxiCloprid%E2%84%A2%20for%20Dogs · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11988 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12057/Barrier%C2%AE%20for%20dogs · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16707 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16987/MoxiCloprid%E2%84%A2%20for%20Cats · document · SPL

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.

Talk to a Vet / Find a Vet Near You

Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:42 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Advantage Multi™ for Dogs Advantage® DUO Barrier® for cats Barrier® for dogs IMOXI™ Topical Solution for Cats IMOXI™ Topical Solution for Dogs Midamox® for Cats Midamox® for Dogs MoxiCloprid™ for Cats MoxiCloprid™ for Dogs PARASEDGE® Multi for Dogs PARASEDGE™ Multi for Cats advantage multi™ for cats advantus™

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog, No Use Class Stated Or Implied

Rx/OTC: OTC, RX

Form/route: Chewable Tablets, Liquid (Solution), Solution, Topical Solution • Oral, Topical

Applications: ANADA 200-700 • ANADA 200-714 • ANADA 200-818 • ANADA 200-718 • ANADA 200-811 • ANADA 200-701 • ANADA 200-721 • ANADA 200-716 • NADA 141-251 • NADA 141-254 • NADA 141-435 • ANADA 200-638 • ANADA 200-615 • NADA 141-208

Documents: 18 (FOI: 18) • SPL: 14 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 56 • Cat 56 • View

Case summaries: 11 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Fleas (Flea Infestation) Heartworm Disease Intestinal Parasites (Worms) Mange (sarcoptic mange, demodicosis) Pica Sarcoptic Mange (Scabies)

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: B74.8 ICD10_CM: B82.9 ICD10_CM: B86 ICD10_CM: B88.1

Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats. Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin. (Contraindication, High)

Top reaction signals

Behavioural disorder NOS (1) Biting -aggression (see also Skin and appendages disorders) (1) Blindness (1) Chewing - pruritus (see also Oral cavity disorders) (1) Death (1) Diabetes (1) Foaming at the mouth (1) Hair loss NOS (1) Lack of efficacy (ectoparasite) - flea (1) Lack of efficacy (ectoparasite) - flea (1) Lack of efficacy (endoparasite) - heartworm (1) Lack of efficacy (endoparasite) - hookworm (1) Lack of efficacy - NOS (1) Licking at application site (1) Localised hair loss (1) Localised itching (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
17030-023-01	17030	-
17030-023-03	17030	-
17030-025-01	17030	-
17030-025-06	17030	-
17030-043-01	17030	-
17030-043-06	17030	-
17030-044-01	17030	-
17030-044-06	17030	-
17030-080-01	17030	-
17030-080-06	17030	-
17030-103-01	17030	-
17030-103-06	17030	-
17030-400-01	17030	-
17030-400-06	17030	-
17030-500-01	17030	-
17030-500-06	17030	-
51072-100-01	51072	-
51072-100-02	51072	-
51072-100-03	51072	-
51072-100-04	51072	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

ANADA 200-700 FOI Summar.pdf • FOI summary • Official • Dec. 16, 2025
FDA FOI summary for application 200700
FOI Summary oA 200-714 Approved November 24, 2021.pdf • FOI summary • Official • Dec. 5, 2025
FDA FOI summary for application 200714
FOI Summary oA 200-818 Approved August 5, 2025.pdf • FOI summary • Official • Aug. 28, 2025
FDA FOI summary for application 200818
FOI Summary oA 200-718 Approved February 7, 2022.pdf • FOI summary • Official • June 2, 2025
FDA FOI summary for application 200718
FOI Summary oA 200-811 Approved March 24, 2025.pdf • FOI summary • Official • March 28, 2025
FDA FOI summary for application 200811
FOI Summary oA 200-701 Approved June 10, 2021.pdf • FOI summary • Official • Oct. 24, 2023
FDA FOI summary for application 200701
FOI Summary sA 200-701 Approved February 9, 2023.pdf • FOI summary • Official • Oct. 24, 2023
FDA FOI summary for application 200701
FOI Summary oA 200-721 Approved March 28, 2022.pdf • FOI summary • Official • Oct. 10, 2023
FDA FOI summary for application 200721
FOI Summary sA 200-721 Approved January 12, 2023.pdf • FOI summary • Official • Oct. 10, 2023
FDA FOI summary for application 200721
FOI Summary oA 200-716 Approved January 28, 2022.pdf • FOI summary • Official • Aug. 23, 2023
FDA FOI summary for application 200716
UCM051438.pdf • FOI summary • Official • Feb. 2, 2023
FDA FOI summary for application 141251
UCM381705.pdf • FOI summary • Official • Feb. 2, 2023
FDA FOI summary for application 141251
UCM051423.pdf • FOI summary • Official • Aug. 22, 2022
FDA FOI summary for application 141254
UCM381709.pdf • FOI summary • Official • Aug. 22, 2022
FDA FOI summary for application 141254
UCM433795.pdf • FOI summary • Official • May 21, 2021
FDA FOI summary for application 141435
FOI Summary oA 200-638 Approved May 27, 2020.pdf • FOI summary • Official • June 1, 2020
FDA FOI summary for application 200638
FOI Summary oA 200-615 Approved December 19, 2019.pdf • FOI summary • Official • Dec. 30, 2019
FDA FOI summary for application 200615
ucm117758.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141208

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 21 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not administer this product orally. For the first 30 minutes after app… (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Lack of efficacy (ectoparasite) - flea, Pruritus, Lethargy (see also Central nervous system depression in 'Neurological'), La… (Official, 2026-02-12)
usage: For the prevention of heartworm disease caused by Dirofilaria immitis ; kills adult fleas and is indicated for the treatment of flea infestations ( Ctenocephal… (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
PARASEDGE® Multi for Dogs RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Virbac AH, Inc.	ANADA 200-700	Approved	Dec 16, 2025
Barrier® for cats RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Aurora Pharmaceutical, Inc.	ANADA 200-714	Approved	Dec 5, 2025
MoxiCloprid™ for Dogs RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Bimeda Animal Health Limited	ANADA 200-818	Approved	Aug 28, 2025
Barrier® for dogs RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Aurora Pharmaceutical, Inc.	ANADA 200-718	Approved	Jun 2, 2025
MoxiCloprid™ for Cats RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Bimeda Animal Health Limited	ANADA 200-811	Approved	Mar 28, 2025
PARASEDGE™ Multi for Cats RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Virbac AH, Inc.	ANADA 200-701	Approved	Oct 24, 2023
Midamox® for Cats RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Norbrook Laboratories, Ltd.	ANADA 200-721	Approved	Oct 10, 2023
Midamox® for Dogs RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Norbrook Laboratories, Ltd.	ANADA 200-716	Approved	Aug 23, 2023
Advantage Multi™ for Dogs RX Imidacloprid Moxidectin Liquid (Solution) • Topical Label highlights Official documents	Elanco US Inc.	NADA 141-251	Approved	Feb 2, 2023
advantage multi™ for cats RX Imidacloprid Moxidectin Solution • Topical Label highlights Official documents	Elanco US Inc.	NADA 141-254	Approved	Aug 22, 2022
advantus™ OTC Imidacloprid Chewable Tablets • Oral Label highlights Official documents	Elanco US Inc.	NADA 141-435	Approved	May 21, 2021
IMOXI™ Topical Solution for Cats RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Vetoquinol USA, Inc.	ANADA 200-638	Approved	Jun 1, 2020
IMOXI™ Topical Solution for Dogs RX Imidacloprid Moxidectin Topical Solution • Topical Label highlights Official documents	Vetoquinol USA, Inc.	ANADA 200-615	Approved	Dec 30, 2019
Advantage® DUO RX Imidacloprid Ivermectin Liquid (Solution) • Topical Label highlights Official documents	Elanco US Inc.	NADA 141-208	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin

Dogs

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

10% imidacloprid and 1% moxidectin

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations

Ferrets

Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose for a ferret is 9 m/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin

Dogs

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

10% (100 mg) imidacloprid and 2.5% (25 mg) moxidectin per milliliter

Dogs

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations

Ferrets

Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 0.45 mg/lb (1 mg/kg) moxidectin, once a month, by topical administration.

Limitations

Ferrets

Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration. Only
the 0.4 mL applicator tube volume (PARASEDGE™ Multi 9) should be used on ferrets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Cat, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

Cats

Indication

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations

Ferrets

Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2mg/kg) moxidectin, once a month, by topical administration. Only the 0.4 mL applicator volume (Midamox 9) should be used on ferrets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin

Dogs

Indication

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains 100 milligrams (mg) imidacloprid and 25 mg moxidectin.

Dogs

Indication

Dosage

Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg)moxidectin, once a month.

Limitations

Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats.

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of solution contains 100 mg imidacloprid and 10 mg moxidectin

Ferrets

Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Limitations

Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme); kills adult fleas and treats flea infestations (Ctenocephalides felis).

Dosage

Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.

Limitations

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick, debilitated, or underweight cats. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not apply to irritated skin.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each chewable tablet contains either 7.5 mg or 37.5 mg of imidacloprid.

Dogs

Indication

advantus™ kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.

Dosage

Administer daily one 7.5-mg chew to dogs weighing 4 to 22 pounds or one 37.5-mg chew to dogs weighing 23 to 110 pounds.

Limitations

Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one tablet a day.

FDA page: Open in Animal Drugs @ FDA

Species: Cat, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin

Cats

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworm (Toxocara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10.0 mg/kg) imidacloprid and 0.45 mg/lb. (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin

Dogs

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

The product is available in unit applicator tubes containing 0.4, 1.0, 2.5, or 4.0 milliliters. Each milliliter of solution contains 100 milligrams imidacloprid and 800 micrograms ivermectin.

Dogs

Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis).

Dosage

The recommended minimum dosage is 4.5 milligram per pound (10 milligram per kilogram) of imidacloprid and 36.4 micrograms per pound (80 micrograms per kilogram) of ivermectin, topically once a month.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI ANADA 200-700 FOI Summar.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).

SPL Packages

PARASEDGE® Multi for Dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-714 Approved November 24, 2021.pdf

Summary

Cats: For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).
Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.

SPL Packages

Barrier® for cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-818 Approved August 5, 2025.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.

SPL Packages

MoxiCloprid™ for Dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-718 Approved February 7, 2022.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

Barrier® for dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-811 Approved March 24, 2025.pdf

Summary

Cats: For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

SPL Packages

MoxiCloprid™ for Cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary sA 200-701 Approved February 9, 2023.pdf

Summary

This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
FOI FOI Summary oA 200-701 Approved June 10, 2021.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).

SPL Packages

PARASEDGE™ Multi for Cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary sA 200-721 Approved January 12, 2023.pdf

Summary

This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
FOI FOI Summary oA 200-721 Approved March 28, 2022.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

SPL Packages

Midamox® for Cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-716 Approved January 28, 2022.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

Midamox® for Dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM381705.pdf

Summary

This supplement provides for the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs and the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.
FOI UCM051438.pdf

Summary

ADVANTAGE MULTI for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Dogs kills adult fleas and is indicated for the treatment of flea infestations ( Ctenocephalides felis). ADVANTAGE MULTI for Dogs is also indicated for the treatment and control of the following intestinal parasites:

SPL Packages

Advantage Multi™ for Dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM381709.pdf

Summary

This supplement provides for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
FOI UCM051423.pdf

Summary

ADVANTAGE MULTI for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Cats kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations. ADVANTAGE MULTI for Cats is also indicated for the treatment and control of ear mite ( Otodectes cynotis) infestations and the following intestinal parasites:

SPL Packages

advantage multi™ for cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI UCM433795.pdf

Summary

Advantus™ kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.

SPL Packages

advantus™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-638 Approved May 27, 2020.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

SPL Packages

IMOXI™ Topical Solution for Cats (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-615 Approved December 19, 2019.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

IMOXI™ Topical Solution for Dogs (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm117758.pdf

Summary

For the prevention of heartworm disease caused by Dirofilaria immitis. Also indicated for the treatment of flea infestation ( Ctenocephalides felis).

SPL Packages

Advantage® DUO (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

For the prevention of heartworm disease caused by Dirofilaria immitis ; kills adult fleas and is indicated for the treatment of flea infestations ( Ctenocephalides felis ). For the prevention of heartworm disease caused by Dirofilaria immitis ; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms ( Toxocara canis and Toxascaris leonina ), hookworms ( Ancylostoma caninum and Uncinaria stenocephala ), and whipworms ( Trichuris vulpis ); kills adult fleas and treats flea infestations ( Ctenocephalides felis ); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis . For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis ; kills adult fleas ( Ctenocephalides felis ) and is indicated for the treatment of flea infestations on ferrets.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog

Digestive

Diarrhea (531) Vomiting (491) Loss of appetite (333)

Skin & allergy

Itching (1000) Itching (3) Itching (3) Itching (2) Itching (2)

Neurologic

Tiredness (lethargy) (753) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3) Tiredness (lethargy) (3)

Behavior

Behavioral disorder (unspecified) (519) Behavioral disorder (unspecified) (3) Behavioral disorder (unspecified) (3) Behavioral disorder (unspecified) (2) Behavioral disorder (unspecified) (2) Behavioral disorder (unspecified) (2) Behavioral disorder (unspecified) (2)

Effectiveness

Lack of efficacy (ectoparasite) - flea (2306) Lack of efficacy (endoparasite) - heartworm (532) Lack of efficacy (ectoparasite) - flea (15) Lack of efficacy (ectoparasite) - flea (15) Lack of efficacy (ectoparasite) - flea (15) Lack of efficacy (ectoparasite) - flea (15) Lack of efficacy (ectoparasite) - flea (14) Lack of efficacy (ectoparasite) - flea (14) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - hookworm (5) Lack of efficacy (endoparasite) - heartworm (3) Lack of efficacy (endoparasite) - heartworm (3) Lack of efficacy (endoparasite) - heartworm (3) Lack of efficacy (endoparasite) - heartworm (3) Lack of efficacy (endoparasite) - heartworm (3) Lack of efficacy (endoparasite) - heartworm (3)

Other

Other abnormal test result NOS (4) Other abnormal test result NOS (4) Other abnormal test result NOS (4) Other abnormal test result NOS (4) Other abnormal test result NOS (4) Other abnormal test result NOS (4) Death (3) Death (3) Death (3) Death (3) Death (3) Death (3) Not eating (3) Not eating (3)

Cat

Digestive

Drooling (418) Loss of appetite (192) Vomiting (188)

Skin & allergy

Itching (471) Hair loss at application site (344) Application site hair loss (1) Application site hair loss (1) Application site hair loss (1) Application site hair loss (1) Application site hair loss (1) Application site hair loss (1) Chewing - pruritus (1) Chewing - pruritus (1) Chewing - pruritus (1) Chewing - pruritus (1) Chewing - pruritus (1) Chewing - pruritus (1) Hair loss NOS (1) Hair loss NOS (1) Hair loss NOS (1) Hair loss NOS (1) Hair loss NOS (1) Hair loss NOS (1)

Neurologic

Tiredness (lethargy) (443)

Behavior

Behavioral disorder (unspecified) (402) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Behavioral disorder (unspecified) (1) Biting -aggression (1) Biting -aggression (1) Biting -aggression (1) Biting -aggression (1) Biting -aggression (1) Biting -aggression (1)

Effectiveness

Lack of efficacy (ectoparasite) - flea (1011)

Other

Foaming at the mouth (2) Foaming at the mouth (2) Foaming at the mouth (2) Foaming at the mouth (2) Foaming at the mouth (2) Foaming at the mouth (2) Death (1) Death (1) Death (1) Death (1) Death (1) Death (1) Diabetes (1) Diabetes (1) Diabetes (1) Diabetes (1) Diabetes (1) Diabetes (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Spaniel - Cocker American, Male, 2.83 year, 10.43 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Loose stool, Lack of efficacy (ectoparasite) - flea • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-055969
Serious AE: No
Treated For AE: No
Sex: Male
Age: 2.83 Year
Weight: 10.430 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Topical
Form: Solution
Dose: 1 tube per animal

Reactions Reported:

Loose stool Lack of efficacy (ectoparasite) - flea

Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 2 year, 3.63 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Foaming at the mouth, Licking at application site • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-055996
Serious AE: No
Treated For AE: No
Sex: Female
Age: 2.00 Year
Weight: 3.630 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Topical
Form: Solution
Dose: 1 tube per animal

Reactions Reported:

Foaming at the mouth Licking at application site

Outcomes: Recovered/Normal

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Male, 14 month, 26.762 kilogram • Drug: MSK, Solution, Unknown • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-055791
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 14.00 Month
Weight: 26.762 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Solution

Reactions Reported:

Lack of efficacy (endoparasite) - heartworm

Outcomes: Ongoing

Dog, Shih Tzu, Female, 3 year, 4.98 kilogram • Drug: MSK, Solution, Topical • Reactions: Reddening of the skin, Skin irritation • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-055994
Serious AE: No
Treated For AE: No
Sex: Female
Age: 3.00 Year
Weight: 4.980 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Topical
Form: Solution

Reactions Reported:

Reddening of the skin Skin irritation

Outcomes: Outcome Unknown

Dog, Chihuahua, Unknown • Drug: MSK, Tablet, chewable, Oral, Dose: 1 Other per animal • Reactions: Lack of efficacy (ectoparasite) - flea, Product label issues, Patient instructions for use on label confusing • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-055814
Serious AE: No
Treated For AE: No
Sex: Unknown

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet, chewable
Dose: 1 Other per animal

Reactions Reported:

Lack of efficacy (ectoparasite) - flea Product label issues Patient instructions for use on label confusing

Outcomes: Outcome Unknown

Dog, Crossbred Canine/dog, Unknown, 6 month, 15.88 kilogram • Drug: MSK, Solution, Unknown • Reactions: Lack of efficacy - NOS, Lack of efficacy (endoparasite) - hookworm • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-055986
Serious AE: No
Treated For AE: Yes
Sex: Unknown
Age: 6.00 Month
Weight: 15.880 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Solution

Reactions Reported:

Lack of efficacy - NOS Lack of efficacy (endoparasite) - hookworm

Outcomes: Outcome Unknown

Dog, Dachshund (unspecified), Unknown • Drug: MSK, Solution, Oral, Dose: 1 dose per animal • Reactions: Blindness • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-056002
Serious AE: Yes
Treated For AE: No
Sex: Unknown

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Solution
Dose: 1 dose per animal

Reactions Reported:

Blindness

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 3.16 year • Drug: MSK, Solution, Topical, Dose: 1 dose per animal • Reactions: Hair loss NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-054257
Serious AE: No
Treated For AE: No
Sex: Female
Age: 3.16 Year

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Topical
Form: Solution
Dose: 1 dose per animal

Reactions Reported:

Hair loss NOS

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on PetWisePlus are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Imidacloprid

Pet Owner Quick Guide

Imidacloprid

Quick Facts

Warnings / Contraindications

Adverse Reactions

Most Reported Reactions

Storage & Handling

Documents

Promotional Materials (Marketing)

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Revision History

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

PARASEDGE® Multi for Dogs • Topical Solution • Topical

Barrier® for cats • Topical Solution • Topical

MoxiCloprid™ for Dogs • Topical Solution • Topical

Barrier® for dogs • Topical Solution • Topical

MoxiCloprid™ for Cats • Topical Solution • Topical

PARASEDGE™ Multi for Cats • Topical Solution • Topical

Midamox® for Cats • Topical Solution • Topical

Midamox® for Dogs • Topical Solution • Topical

Advantage Multi™ for Dogs • Liquid (Solution) • Topical

advantage multi™ for cats • Solution • Topical

advantus™ • Chewable Tablets • Oral

IMOXI™ Topical Solution for Cats • Topical Solution • Topical

IMOXI™ Topical Solution for Dogs • Topical Solution • Topical

Advantage® DUO • Liquid (Solution) • Topical

Official Documents (FDA)

PARASEDGE® Multi for Dogs • 200700

Barrier® for cats • 200714

MoxiCloprid™ for Dogs • 200818

Barrier® for dogs • 200718

MoxiCloprid™ for Cats • 200811

PARASEDGE™ Multi for Cats • 200701

Midamox® for Cats • 200721

Midamox® for Dogs • 200716

Advantage Multi™ for Dogs • 141251

advantage multi™ for cats • 141254

advantus™ • 141435

IMOXI™ Topical Solution for Cats • 200638

IMOXI™ Topical Solution for Dogs • 200615

Advantage® DUO • 141208

Usage

Contraindications

Side Effects

Top Reported Reactions (openFDA)

Adverse Event Case Summaries (openFDA)

Sep 23, 2025 • Dog • Spaniel - Cocker American • Loose stool, Lack of efficacy (ectoparasite) - flea • Outcome Unknown

Sep 22, 2025 • Cat • Domestic Shorthair • Foaming at the mouth, Licking at application site • Recovered/Normal

Sep 22, 2025 • Dog • ['Shepherd (unspecified)', 'Dog (unknown)'] • Lack of efficacy (endoparasite) - heartworm • Ongoing

Sep 22, 2025 • Dog • Shih Tzu • Reddening of the skin, Skin irritation • Outcome Unknown

Sep 19, 2025 • Dog • Chihuahua • Lack of efficacy (ectoparasite) - flea, Product label issues • Outcome Unknown

Sep 19, 2025 • Dog • Crossbred Canine/dog • Lack of efficacy - NOS, Lack of efficacy (endoparasite) - hookworm • Outcome Unknown

Sep 19, 2025 • Dog • Dachshund (unspecified) • Blindness • Recovered/Normal

Sep 12, 2025 • Cat • Domestic Shorthair • Hair loss NOS • Outcome Unknown

Overdose Information

Storage & Handling

Share Your Thoughts